Search results for " Previous pertuzumab"

showing 1 items of 1 documents

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience

2017

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreat…

0301 basic medicineOncologyHER2 positivereal-worldmedicine.medical_specialtyHER2 positive; T-DM1; metastatic breast cancer; previous pertuzumab; real-worldHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1; OncologyT-DM1Previous pertuzumabHER2 positive; metastatic breast cancer; previous pertuzumab; real-world; T-DM1; oncologyECOG Performance Statuslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialSettore MED/04 - PATOLOGIA GENERALElawInternal medicineMedicineUnivariate analysisSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerprevious pertuzumabmedicine.diseaseMetastatic breast cancerMetastatic breast cancerHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1Log-rank testtrastuzumab030104 developmental biologyOncologychemistryReal-worldTrastuzumab emtansine030220 oncology & carcinogenesisHER2 positive Metastatic breast cancer Previous pertuzumab Real-world T-DM1 Oncologymetastatic breast cancerPertuzumabbusinessmedicine.drugResearch Paper
researchProduct